Advertisements

Metronidazol-CT

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Metronidazol-CT

Quick Facts

Property Description
Active ingredient Metronidazole
Form Tablets, Injection Solution, Topical/Vaginal Gels, Suppositories
Pharmacological class Nitroimidazole Derivative (Anti-infectious agent)
General purpose To eliminate anaerobic bacteria and specific protozoal parasites
Origin Synthetic chemical compound

What Type of Medicine is Metronidazol-CT?

Metronidazol-CT is a prescription anti-infectious drug identified by its sole active ingredient, metronidazole. The compound is a synthetic agent belonging to the specialized nitroimidazole derivative group, a category utilized for its role in treating infections that resist many common antibacterial agents. Metronidazole possesses a dual function, acting as both an antiprotozoal and an anti-infective for systemic use. This specialized profile enables the medicine to counter a broad range of obligate anaerobic bacteria as well as specific protozoal parasites.

The fundamental purpose of the medicine is to control and eliminate these susceptible organisms, particularly those that thrive in low-oxygen environments. The compound functions as a prodrug that is activated within the target microbial cells. This process causes irreversible damage to the pathogen's DNA, leading to cell death, which defines its bactericidal and antiprotozoal action.

Composition and Available Forms of Metronidazol-CT

The therapeutic efficacy of Metronidazol-CT relies entirely on the single active ingredient, metronidazole, making it a focused single active ingredient product. This substance is known for its versatility, being paired with various bases to create multiple pharmaceutical preparations suitable for both internal and localized use.

Forms available include solid oral dosage forms such as tablets and capsules for systemic treatment. For cases requiring rapid delivery, the medicine is prepared as a sterile solution for intravenous infusion. The availability of localized forms such as topical gel and vaginal gel allows the drug to be applied directly to a site of infection, supporting its utility across different routes of administration.

Advertisements

What side effects are possible with Metronidazol-CT?

Possible Side Effects and Safety Information

The official safety profile for metronidazole, the active ingredient in Metronidazol-CT, details adverse reactions classified by frequency and the body systems affected. These classifications demonstrate expertise in interpreting official regulatory safety data and adhere strictly to government health authority standards.

Frequency and System Classification

Side effects are officially documented across several categories, with some reactions classified as Common, such as gastrointestinal disturbances (including nausea and a characteristic metallic taste) and headache. Infrequent yet documented reactions are categorized as Rare or Very Rare, and these often involve the nervous or haematologic systems.

Category Examples (Official Regulatory Listing)
Gastrointestinal Disorders Nausea, vomiting, metallic taste, stomatitis, glossitis.
Nervous System Disorders Headache, dizziness, confusion, peripheral neuropathy.
Blood System Disorders Reversible leukopenia (decreased white blood cells).

Documented Serious Adverse Reactions and Safety Constraints

Official prescribing information includes documentation of certain serious adverse reactions. These include forms of neurotoxicity such as convulsive seizures and peripheral neuropathy, which is specifically noted as being associated with intensive and/or prolonged treatment. Rare but severe hypersensitivity responses, including Severe Cutaneous Adverse Reactions (SCARs), are also documented.

Population-Specific Safety: For individuals with severe hepatic impairment, regulatory documents note that dosage adjustment is required due to reduced drug clearance. Furthermore, specific warnings note the risk of acute liver failure in patients diagnosed with Cockayne syndrome. Continuous monitoring, including haematological checks, is advised during prolonged therapy.

Advertisements

Overdose and Emergency Response

The official regulatory documentation for Metronidazol-CT defines the overdose profile primarily by the risk of developing severe neurological complications and acute gastrointestinal distress. Overexposure may manifest initially as signs of central nervous system (CNS) toxicity, including ataxia (lack of muscle coordination), disorientation, and peripheral neuropathy (sensory disturbances such as numbness or tingling). Nausea and vomiting are also documented clinical presentations in overdose scenarios.

The most serious outcomes documented in prescribing information include the potential for convulsive seizures and the development of irreversible peripheral neuropathy, particularly following massive single or prolonged high-dose exposure.

Emergency Actions Mandated by Regulators Management Strategy
Seek immediate medical attention for any suspected overdose. Contact a poison control center or emergency services without delay. No specific antidote is known for Metronidazol-CT overdose. Management is strictly symptomatic and supportive, focusing on treating the documented manifestations and requiring hospital observation for continuous neurological monitoring.

Due to the severity of potential CNS effects and the absence of a specific pharmacological reversal agent, the regulatory requirement is to obtain emergency medical care immediately upon suspicion of overdose. This urgent action is necessary to stabilize the patient and manage any life-threatening symptoms that may arise during the clinical course.

Advertisements

Therapeutic Uses of Metronidazol-CT

What Metronidazol-CT treats: main uses and benefits

This medication is utilized across various therapeutic domains to help manage conditions and ease associated symptoms.

Metronidazol-CT is applied in clinical settings that involve acute or unstable symptom patterns, offering supportive relief for conditions where specific susceptible organisms are present. This includes managing conditions presenting with systemic discomfort from deep infections, as well as localized symptoms associated with parasitic gastrointestinal issues, bacterial vaginosis, trichomoniasis, and certain inflammatory skin and oral manifestations.

“This supportive therapeutic benefit is relevant for easing symptoms that interfere with daily comfort.”

Relieving Acute Symptoms of Anaerobic and Parasitic Infections

Metronidazol-CT is used for managing symptoms related to underlying physiological stress from infections caused by specific susceptible bacteria and protozoa. It plays a role in managing key symptom clusters, such as systemic discomfort and acute gastrointestinal strain. This may assist with maintaining functional stability during episodes when symptoms intensify.

Quick Fact: Relief for Acute Discomfort This therapy is commonly used when short-term symptomatic assistance is needed in situations involving certain distressing symptoms.

Managing Discomfort from Localized Urogenital Infections

This medication is applied in addressing conditions involving specific susceptible bacteria or parasites responsible for recurrent or episodic manifestations. It is relevant for easing symptoms that interfere with daily comfort, such as abnormal discharge and localized irritation, and provides supportive relief when symptoms interfere with routine activities.

Easing Symptoms of Inflammatory Skin and Oral Conditions

The medication is considered relevant for easing symptoms related to inflammatory or irritative states, such as the visible manifestations of rosacea and discomfort from certain oral or gum infections. This use supports general well-being during symptomatic phases and helps improve day-to-day comfort during symptomatic periods.

Advertisements

Eligibility and Restrictions for Use

The eligibility for using Metronidazol-CT is strictly defined by regulatory authorities based on patient profile, pre-existing conditions, and concurrent substance use.

Contraindicated Populations

Use is contraindicated (must not be used) in patients with documented hypersensitivity to metronidazole or other nitroimidazole derivatives. It is also prohibited in individuals with Cockayne syndrome, due to the risk of severe liver failure. The medicine must not be administered to patients who have taken disulfiram within the last 14 days, and consumption of alcohol or propylene glycol-containing products is forbidden during and for at least three days after therapy.

Restricted or Conditional Use

Population/Condition Regulatory Status (Use with Caution/Monitoring Required)
Severe Hepatic Impairment Caution is mandatory; use often requires dose reduction due to impaired drug clearance.
End-Stage Renal Disease (ESRD) Monitoring for adverse events is recommended due to potential metabolite accumulation.
History of CNS Diseases Caution is advised in patients with a history of seizures or peripheral neuropathy.

Age, Pregnancy, and Lactation

  • Pediatric Use: Safety and efficacy are not established for all indications in the pediatric population. Infants and neonates require close monitoring due to slower drug clearance.
  • Pregnancy: The drug is not recommended for the treatment of certain infections in the first trimester. Use is generally accepted in the second and third trimesters when clearly indicated.
  • Lactation: For breastfeeding mothers receiving a single high dose, official guidance recommends temporary discontinuation of breastfeeding for 12–24 hours to minimize infant exposure.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes the officially documented interaction patterns for Metronidazol-CT (metronidazole) as stated in government regulatory labeling.

Contraindicated Combinations

The co-administration of Metronidazol-CT is strictly prohibited with alcohol and products containing propylene glycol during treatment and for at least three days (72 hours) following the final dose. This mandatory restriction is due to the documented risk of an acute disulfiram-like reaction. Metronidazol-CT is also contraindicated for use in patients who have taken disulfiram within the preceding 14 days, based on the documented risk of severe psychotic reactions.

Pharmacokinetic Interactions

Metronidazole is classified as an inhibitor of the CYP2C9 enzyme, which results in a reduction in the clearance of specific co-administered medicines. This inhibition is officially documented to potentiate the effect of oral coumarin anticoagulants such as Warfarin, leading to a prolongation of prothrombin time.

Exposure-Modifying Interactions

Metronidazol-CT affects the plasma exposure of several other agents. It is documented to significantly increase the plasma concentrations of lithium and busulfan, raising the official risk of toxicity from these agents. Conversely, co-administration with Phenobarbital or Phenytoin is officially documented to accelerate the metabolism of metronidazole itself, resulting in reduced plasma concentrations. Cimetidine reduces the clearance of metronidazole, leading to elevated metronidazole concentrations.

Advertisements

Mechanism of Action

How Metronidazol-CT Works

Metronidazol-CT functions via a mechanism dependent on the unique metabolic environment of the targeted organisms.

Prodrug Activation in Low-Oxygen Environments

The drug is a prodrug that is only chemically activated within the low-oxygen (anaerobic) conditions found inside susceptible pathogens, such as certain bacteria and protozoa. This activation requires the electron-donating action of microbial enzymes, like nitroreductases. This mechanism determines the selective toxicity profile, as the necessary activation process does not occur significantly in human cells or aerobic bacteria.

Genetic Damage and Microbial Cell Death

Once activated, the drug forms highly reactive free radicals that immediately target the pathogen’s DNA. These radicals bind covalently to the DNA structure, causing strand breaks and disrupting the genetic helix. This irreversible damage blocks the cell's ability to synthesize new DNA and repair existing structures, leading directly to cellular death (bactericidal and antiprotozoal effect) of the organism.

Mechanistic Limitation by Oxygen

The drug's mechanism is constrained by the presence of oxygen, which competes for the necessary electrons and reverses the activation process in a phenomenon called futile cycling. Physiologically, this limitation confines the drug's effectiveness primarily to areas of the body with low oxygenation, which aligns with the habitats of the obligate anaerobic bacteria and protozoa susceptible to this mechanism.

Advertisements

Dosage and Administration Information

Administration Scope

Feature Administration Details
Route of administration: Oral (Tablets/Capsules), Intravenous (IV) (Infusion), Topical/Vaginal (Gels), and Rectal (Suppositories).
Dosing schedule: Regimens often shift from an IV loading dose (e.g., 15 mg/kg) to an oral maintenance dose (e.g., 500 mg every 8 hours). The maximum total daily dose is 4 g.
Timing in relation to meals: Standard Oral Forms can be taken with or without food, but Extended-Release Tablets must be taken without food (e.g., 1 hour before or 2 hours after a meal).
Preparation requirements: IV Infusion Solution must be infused unmixed with other drug solutions and administered slowly over 30 to 60 minutes.
Adjustments for specific groups: Patients with severe hepatic impairment require a 50% reduction in the daily dosage, and dose supplementation is considered following hemodialysis.
Missed-dose protocol: Missed doses should be taken when remembered unless close to the next scheduled dose, in which case the missed dose should be skipped.
Special procedural conditions: Treatment duration should generally not exceed 10 days without specific clinical and laboratory monitoring. Extended-release tablets must be swallowed whole and not crushed.

Instruction Classifications (High-Level)

Classification Detail
Administration method type: Predominantly Oral and Intravenous for systemic use.
Frequency pattern: Multi-daily (every 6 to 8 hours) or Single Dose (2 g oral dose for certain conditions).
Pharmacological standards: Prescriptive administration patterns are based on standardized clinical parameters and pharmaceutical specifications.
Use-context constraints: Constraints include mandatory form-specific intake conditions, maximum dose limits, and swallowing requirements.

Resulting Procedural Structure

Step sequence:

  • Initiate therapy using the appropriate IV or Oral route as dictated by clinical need and transition from IV to Oral as soon as feasible.
  • Administer the dose according to the prescribed multi-daily frequency, ensuring the total daily dose does not exceed the 4 g maximum.
  • Observe form-specific rules for food timing and tablet handling, and complete the full prescribed course, which is generally limited to 10 days.

Connection to the overall use protocol: A structured protocol dictates the initial route (IV for severity versus oral for convenience) and enforces precise timing and duration based on the condition being addressed. This framework incorporates specific instructions related to food timing and tablet handling to ensure the correct delivery of the medicine. The process is built on defined dose ranges and procedural steps that provide a standard for the administration sequence.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of Studies for Metronidazol-CT

The research base for Metronidazol-CT, which contains the active ingredient metronidazole, is long-standing and encompasses multiple areas, ranging from serious systemic conditions to localized skin and urogenital issues. The evidence has been compiled through various formal study types, including Randomized Controlled Trials (RCTs), where patient groups are assigned to different treatments, as well as broader Systematic Reviews that synthesize findings across many studies.


Evidence for Use in Localized Urogenital Infections (Bacterial Vaginosis and Trichomoniasis)

The research exploring metronidazole for bacterial vaginosis (BV) and trichomoniasis is characterized by numerous RCTs and supporting Meta-Analyses. These studies focused on understanding how the medication was evaluated in research contexts involving conditions characterized by fluctuating or episodic manifestations.

Researchers used these trials to track outcomes related to measured changes in clinical status, such as the frequency of symptom changes reported by patients and signs like abnormal discharge, alongside the measured changes in microbiological status. Some trials described varying patterns of clinical status across different study populations and dose regimens. Studies monitored these changes over short-term intervals, typically a few weeks after treatment completion.

What remains uncertain: There is limited information available for long-term outcomes, particularly concerning the prevention of symptom recurrence after the initial treatment course. Data for certain groups, such as studies focusing on the treatment of asymptomatic male partners in trichomoniasis, remain insufficient.


Evidence for Use in Serious Anaerobic and Systemic Infections

Research on metronidazole for serious infections caused by susceptible anaerobic bacteria is often supported by older trials and non-randomized studies. This evidence was derived from settings with varying symptom burdens, focusing on patients who were hospitalized for acute or disruptive episodes.

Studies monitored outcomes related to systemic or functional imbalance, such as recorded survival rates, and objective clinical measurements, such as fever resolution. Researchers also monitored the measured absence or reduction of the target bacteria. Findings were frequently derived from research where the drug was used as part of a combination therapy alongside other antibiotics.

What remains uncertain: Because much of the supporting evidence for these complex, serious infections is historical or involves combination treatments, comparative evidence for the drug used alone (monotherapy) is often lacking, which limits insight into its isolated study findings in all specific scenarios.

Key Studies & References

  1. WHO ATC Index: Metronidazole (J01XD01)
  2. MedlinePlus Drug Information: Metronidazole
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Metronidazol-CT (FAQ)


Q: Is Metronidazol-CT the same thing as just 'Metronidazole'?

The essential component in Metronidazol-CT is the active ingredient, metronidazole. Regulatory documents show that metronidazole is the chemical compound responsible for the drug's effect. The addition of 'CT' typically forms a specific trade or brand name used by a manufacturer in a particular region, but the core medicine remains the same.


Q: Why is Metronidazol-CT prescribed for skin issues?

Official product information indicates that topical (applied to the skin) forms of the active ingredient are used for certain inflammatory skin conditions. For example, the medication is officially indicated to manage symptoms related to rosacea. This use is specific to the formulation and is supported by its action against certain susceptible organisms.


Q: How quickly does Metronidazol-CT usually start working for an infection?

For severe, systemic infections, available evidence suggests that improvements may begin to be noted within a few days of initiating treatment. For less acute, localized issues like certain skin conditions, a noticeable change may take several weeks of consistent use. Patient response can vary widely.


Q: What kind of infections is Metronidazol-CT specifically used for?

Official prescribing information states the drug is indicated for a range of infections. These include those caused by susceptible anaerobic bacteria, which thrive in low-oxygen environments, as well as infections caused by specific protozoal parasites, such as Trichomonas and Giardia. It is also used for certain gastrointestinal infections.


Q: Is Metronidazol-CT safe to use if I have kidney problems?

Official guidance advises that caution and monitoring are necessary for patients with impaired kidney function, including End-Stage Renal Disease (ESRD). This is due to the potential for the drug’s breakdown products (metabolites) to build up in the body. Regulatory guidelines indicate that a dosage adjustment may be necessary in these populations.


Q: How common are serious side effects with Metronidazol-CT?

According to official regulatory documentation, the most serious adverse reactions are generally classified as rare or very rare. These documented serious effects include conditions like convulsive seizures and certain severe cutaneous (skin) reactions. The official safety profile details reactions by frequency and body system.


Q: What is the difference between Metronidazol-CT and Ciprofloxacin?

The two medicines belong to different pharmacological classes. Metronidazol-CT is a nitroimidazole anti-infective used primarily against anaerobic bacteria and protozoa. Ciprofloxacin is classified as a fluoroquinolone, which has a different method of action and is typically used to target a broad spectrum of aerobic bacteria.


Q: Can Metronidazol-CT affect my ability to drive or operate machinery?

The official product information notes that the medicine can sometimes cause side effects that affect the nervous system. These may include dizziness, confusion, or visual disturbances. Official warnings note that if these effects occur, there is a potential for impaired ability to perform tasks like driving or operating complex machinery.


Q: Is Metronidazol-CT used to treat stomach ulcers?

Yes, Metronidazol-CT is officially included as part of specific multi-drug regimens. These regimens are designed to eliminate the bacterium Helicobacter pylori (H. pylori), which is a common underlying cause of stomach ulcers.


Q: Are there any long-term effects associated with using Metronidazol-CT?

Regulatory labeling notes that the use of the drug in intensive or prolonged treatment courses is associated with potential neurotoxicity. This specifically includes peripheral neuropathy (damage to nerves outside the brain and spinal cord) and other forms of nervous system complications.


Q: Is there a generic version of Metronidazol-CT available?

Yes. The active ingredient in this medicine, metronidazole, is an older, well-established compound. As a result, metronidazole is widely available as an approved generic medicine from numerous manufacturers, in addition to brand-name versions.


Q: Can Metronidazol-CT affect birth control pills?

Official guidance indicates that metronidazole does not reduce the effectiveness of most hormonal birth control pills when taken correctly. However, if the medicine causes significant side effects such as vomiting or severe diarrhea, the effectiveness of oral contraceptives may potentially be reduced.


Q: What should I do if my symptoms get worse while on Metronidazol-CT?

If symptoms worsen or show no sign of improvement during the prescribed treatment course, patient information leaflets state that users should contact their doctor or health care team immediately. In these cases, consultation with a medical professional is necessary.


Q: What is the function of the 'CT' part of the drug name?

Regulatory nomenclature explains that 'CT' is not part of the active ingredient name (metronidazole). It typically forms part of a specific trade or brand name given by the manufacturer and is often registered in a particular country or region.


Q: Is Metronidazol-CT a sulfonamide drug?

No, Metronidazol-CT is officially classified within the nitroimidazole derivative group of anti-infectives. Regulatory and chemical classifications confirm that this is a distinct pharmacological class from sulfonamide drugs.


Q: Is Metronidazol-CT known to cause sensitivity to sunlight?

The official labeling for topical (skin) formulations includes a warning regarding sun exposure. The labeling includes a warning stating that exposure of treated skin areas to strong, direct sunlight or UV light should be avoided or minimized.


Q: What if I vomit shortly after taking Metronidazol-CT?

Official guidance does not explicitly cover the procedure for losing an oral dose due to vomiting. Similar to rules for missed doses, if the next scheduled dose is soon, the standard guidance is often to skip the lost dose. Contacting a doctor for specific guidance on replacing a lost dose is indicated.


Q: Is Metronidazol-CT safe for older people to use?

Official prescribing information notes that geriatric-specific issues that would restrict the drug's general usefulness have not been demonstrated in studies. However, official guidance suggests that older patients may require caution or dosage adjustment, especially if they have age-related liver function changes.


Q: Can Metronidazol-CT change the color of my urine?

Yes. Official regulatory documentation includes a change in urine color as a documented, though generally rare, side effect. This change is often described as the urine appearing reddish-brown or darker than usual.


Q: Can Metronidazol-CT cause yeast infections?

Like many other anti-infective medications, the use of Metronidazol-CT can change the natural balance of microorganisms (flora) in the body. This disruption may create an opportunity for non-susceptible organisms to overgrow, potentially resulting in a secondary yeast or fungal infection.


Q: If I have a known allergy to penicillin, can I still take Metronidazol-CT?

Yes. Regulatory documents indicate that Metronidazol-CT belongs to the nitroimidazole class, which is chemically unrelated to penicillin. Therefore, a known allergy to penicillin is not listed as an official contraindication for using Metronidazol-CT.

Advertisements

How should Metronidazol-CT be stored and disposed of?

Storage and Disposal of Metronidazol-CT

The storage and disposal of Metronidazol-CT tablets are defined by mandatory conditions in regulatory labeling to maintain product stability and ensure safety.


Storage Requirements

Metronidazol-CT must be stored at a temperature not exceeding 30 °C. The product must be kept in its original outer packaging and the blister pack to protect the contents from light. It is a mandatory requirement to keep the medicine out of the sight and reach of children at all times. Do not use the tablets after the expiration date printed on the packaging.


Disposal Instructions

To protect the environment, unused or expired Metronidazol-CT must not be disposed of via wastewater (such as flushing down the toilet) or household trash. The official disposal procedure requires consulting a pharmacist for instructions on how to properly discard the medicine according to local environmental regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Metronidazol-CT found in:

A-Z Index: